Article
BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.
Medicina (Kaunas, Lithuania) - 10 Dec 2022
Darabi Sourat, Braxton David R, Xiu Joanne, Carneiro Benedito A, Swensen Jeff, Antonarakis Emmanuel S, Liu Stephen V, McKay Rana R, Spetzler David, El-Deiry Wafik S, Demeure Michael J
Abstract excerpt
Background: Reversion mutations in BRCA1/2, resulting in restoration of the open reading frame, have been identified as a mechanism of resistance to platinum-based chemotherapy or PARP inhibition. We sought to explore the incidence of BRCA1/2 reversion mutations in different tumor types. Methods: We retrospectively analyzed molecular profiling results from primary and/or metastatic tumor samples submitted by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.